Ilumetri

Tildrakizumab, the active ingredient in Ilumetri, is a IL-23 inhibitor presented as a 100 mg solution for subcutaneous injection use. It treats moderate-to-severe plaque psoriasis in adult patients.\n\nGNH India supplies Ilumetri as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ilumetri (tildrakizumab) targets the interleukin‑23 pathway, a key driver in plaque psoriasis.\n\nModerate-to-severe plaque psoriasis: reduces skin plaque formation and disease activity in adult patients.

Common Side Effects:\n- Injection site pain or erythema\n- Upper respiratory tract infection\n- Headache\n- Fatigue\n\nSerious or Rare Side Effects:\n- Severe allergic reactions (anaphylaxis)\n- Opportunistic infections, including tuberculosis\n- Malignancies such as lymphoma or skin cancer

Before initiating therapy, evaluate the patient for active infections and immunization status.\n\nScreen for active infections: assess and treat before starting Ilumetri\nVaccinations: update required vaccines prior to treatment\nMonitor for signs of infection: report fever, cough, or unusual symptoms promptly\nAssess for hypersensitivity: discontinue if severe allergic reaction occurs\nPregnancy and lactation: use only if potential benefit justifies potential risk\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake

Ilumetri may interact with other agents that affect immune function.\n\nMajor Interactions (Avoid):\n- Live vaccines: contraindicated during therapy\n- Systemic immunosuppressants (e.g., cyclosporine): may increase infection risk\n- Concurrent biologics targeting IL‑12/23 (e.g., ustekinumab): avoid simultaneous use\n\nModerate Interactions (Monitor Closely):\n- Systemic corticosteroids: may augment immunosuppression\n- Antifungal agents (e.g., azoles): monitor for additive infection risk\n- Non‑live vaccines: may have reduced efficacy, assess response